Assessment of Tenofovir-Induced Nephrotoxicity Development and Recovery in HIV Patients on TDF Based Regimens at Kenyatta National Hospital Comprehensive Care Clinic

Abstract

TDF containing HAART is currently the most approved global HIV first-line treatment. Despite its accessibility as a mixture single-tablet regimen for once daily dosing, favorable safety profile and resistance, and effective antiviral activity, it is associated with renal impairment among patients with concurrent use of protease inhibitors and those with advanced HIV virus.